Published in PLoS One on March 22, 2012
Temporal dynamics of glyoxalase 1 in secondary neuronal injury. PLoS One (2014) 0.83
Intrinsic up-regulation of 2-AG favors an area specific neuronal survival in different in vitro models of neuronal damage. PLoS One (2012) 0.79
Daytime-Dependent Changes of Cannabinoid Receptor Type 1 and Type 2 Expression in Rat Liver. Int J Mol Sci (2017) 0.75
Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 16.31
A simple method for organotypic cultures of nervous tissue. J Neurosci Methods (1991) 14.18
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 13.60
Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci (1999) 10.61
Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurosci Res (1993) 9.81
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature (1996) 8.99
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
The molecular logic of endocannabinoid signalling. Nat Rev Neurosci (2003) 7.78
2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun (1995) 6.55
CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science (2003) 5.22
Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature (2003) 4.60
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol (2004) 3.38
Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem (2003) 2.75
The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron (2006) 2.55
Acute spinal cord injury, part I: pathophysiologic mechanisms. Clin Neuropharmacol (2001) 2.14
Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry (2006) 2.01
Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci U S A (2009) 1.64
Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J Biol Chem (2008) 1.60
Cannabinoid receptor and N-acyl phosphatidylethanolamine phospholipase D--evidence for altered expression in multiple sclerosis. Brain Pathol (2011) 1.52
Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci (2003) 1.49
Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem (2010) 1.49
Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol (2002) 1.40
Modulation of the endocannabinoid system: neuroprotection or neurotoxicity? Exp Neurol (2010) 1.31
Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett (2001) 1.30
P2X7 receptors control 2-arachidonoylglycerol production by microglial cells. Proc Natl Acad Sci U S A (2004) 1.25
Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem J (2004) 1.25
Early microglial activation following neonatal excitotoxic brain damage in mice: a potential target for neuroprotection. Neuroscience (2003) 1.20
Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp Neurol (2010) 1.19
N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA). Prog Lipid Res (2010) 1.17
Enzymatic machinery for endocannabinoid biosynthesis associated with calcium stores in glutamatergic axon terminals. J Neurosci (2008) 1.14
Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J Neurochem (2001) 1.13
Neuroprotection: challenges and opportunities. Arch Neurol (2007) 1.11
Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. Pain (2007) 1.09
R-flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids. PLoS One (2010) 1.08
Proinflammatory stimuli control N-acylphosphatidylethanolamine-specific phospholipase D expression in macrophages. Mol Pharmacol (2011) 1.07
Endocannabinoid hydrolases. Prostaglandins Other Lipid Mediat (2002) 1.07
Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke (2002) 1.04
CB1 cannabinoid receptor induction in experimental stroke. Ann Neurol (2000) 1.03
Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. Br J Pharmacol (2004) 1.02
Activation of cannabinoid CB2 receptor ameliorates atherosclerosis associated with suppression of adhesion molecules. J Cardiovasc Pharmacol (2010) 1.00
Endogenous nitric oxide is a key promoting factor for initiation of seizure-like events in hippocampal and entorhinal cortex slices. J Neurosci (2009) 0.98
Changes in brain levels of N-acylethanolamines and 2-arachidonoylglycerol in focal cerebral ischemia in mice. J Neurochem (2007) 0.98
Biological functions and metabolism of oleoylethanolamide. Lipids (2008) 0.97
High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann Neurol (2005) 0.97
Mechanisms of neural cell death: implications for development of neuroprotective treatment strategies. NeuroRx (2004) 0.96
Cannabinoid-mediated inhibition of recurrent excitatory circuitry in the dentate gyrus in a mouse model of temporal lobe epilepsy. PLoS One (2010) 0.96
Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome. Neuroscience (2007) 0.95
Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J Neurochem (2003) 0.93
Cannabinoids and neuronal damage: differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures. Exp Neurol (2006) 0.93
Biochemical and neurochemical sequelae following mild traumatic brain injury: summary of experimental data and clinical implications. Neurosurg Focus (2010) 0.92
Predominant expression of lysosomal N-acylethanolamine-hydrolyzing acid amidase in macrophages revealed by immunochemical studies. Biochim Biophys Acta (2007) 0.92
Proteolytic activation and glycosylation of N-acylethanolamine-hydrolyzing acid amidase, a lysosomal enzyme involved in the endocannabinoid metabolism. Biochim Biophys Acta (2007) 0.91
Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons. Neuropharmacology (2008) 0.90
Palmitoylethanolamide stimulation induces allopregnanolone synthesis in C6 Cells and primary astrocytes: involvement of peroxisome-proliferator activated receptor-α. J Neuroendocrinol (2011) 0.88
Entorhinal cortex lesion in the mouse induces transsynaptic death of perforant path target neurons. Brain Pathol (2004) 0.87
Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia. Neurotox Res (2001) 0.86
Inhibition of microglial fatty acid amide hydrolase modulates LPS stimulated release of inflammatory mediators. FEBS Lett (2007) 0.86
In vivo activation of endocannabinoid system in temporal lobe epilepsy with hippocampal sclerosis. Brain (2011) 0.86
Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferator-activated receptor-α. Neurotox Res (2010) 0.85
Nitric oxide modulates low-Mg2+-induced epileptiform activity in rat hippocampal-entorhinal cortex slices. Neurobiol Dis (2002) 0.84
Structural reorganization of the dentate gyrus following entorhinal denervation: species differences between rat and mouse. Prog Brain Res (2007) 0.84
Enhanced anandamide degradation is associated with neuronal apoptosis induced by the HIV-1 coat glycoprotein gp120 in the rat neocortex. J Neurochem (2004) 0.84
The role of axonal sprouting in functional reorganization after CNS injury: lessons from the hippocampal formation. Restor Neurol Neurosci (2001) 0.83
An organotypic hippocampal slice culture model of excitotoxic injury induced spontaneous recurrent epileptiform discharges. Brain Res (2010) 0.83
An investigation into the early stages of the inflammatory response following ibotenic acid-induced neuronal degeneration. Neuroscience (1990) 0.81
Remote microglial activation in the quinolinic acid model of Huntington's disease. Exp Neurol (1993) 0.81
Sprouting in the hippocampus is layer-specific. Trends Neurosci (1997) 0.80
The cannabinoid WIN 55,212-2-mediated protection of dentate gyrus granule cells is driven by CB1 receptors and modulated by TRPA1 and Cav 2.2 channels. Hippocampus (2011) 0.78
The anatomy of the rat fascia dentata--new vistas. Ann Anat (1997) 0.78
The endocannabinoid N-arachidonoyldopamine (NADA) exerts neuroprotective effects after excitotoxic neuronal damage via cannabinoid receptor 1 (CB(1)). Neuropharmacology (2011) 0.78
GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med (2006) 3.38
Inhibition of GTP cyclohydrolase attenuates tumor growth by reducing angiogenesis and M2-like polarization of tumor associated macrophages. Int J Cancer (2012) 2.80
Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem (2003) 2.75
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst (2006) 2.51
Clinical review: behavioral interventions to prevent childhood obesity: a systematic review and metaanalyses of randomized trials. J Clin Endocrinol Metab (2008) 2.45
Pattern of neuropathic pain induced by topical capsaicin application in healthy subjects. Pain (2015) 2.07
Opioids for chronic non-cancer pain. BMJ (2013) 2.07
Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat (2007) 2.01
Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem (2005) 1.83
The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics (2002) 1.80
Defective brain development in mice lacking the Hif-1alpha gene in neural cells. Mol Cell Biol (2003) 1.75
Capturing adenylyl cyclases as potential drug targets. Nat Rev Drug Discov (2009) 1.66
Reliable screening for a pain-protective haplotype in the GTP cyclohydrolase 1 gene (GCH1) through the use of 3 or fewer single nucleotide polymorphisms. Clin Chem (2007) 1.64
Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. J Invest Dermatol (2003) 1.59
Chain length-specific properties of ceramides. Prog Lipid Res (2011) 1.57
No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing. Trends Neurosci (2009) 1.54
Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet (2004) 1.51
Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance. Pharmacogenomics (2006) 1.50
COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther (2005) 1.46
Pharmacokinetics of non-intravenous formulations of fentanyl. Clin Pharmacokinet (2013) 1.46
Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther (2002) 1.46
Antibodies to cannabinoid type 1 receptor co-react with stomatin-like protein 2 in mouse brain mitochondria. Eur J Neurosci (2013) 1.45
Apoptotic cells promote macrophage survival by releasing the antiapoptotic mediator sphingosine-1-phosphate. Blood (2006) 1.40
Opioids as modulators of cell death and survival--unraveling mechanisms and revealing new indications. Pharmacol Rev (2004) 1.40
FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J Immunol (2007) 1.38
Epigenetics in pain and analgesia: an imminent research field. Eur J Pain (2010) 1.34
Ziconotide for treatment of severe chronic pain. Lancet (2010) 1.34
Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther (2003) 1.31
The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem Biodivers (2007) 1.31
Tumor cell apoptosis polarizes macrophages role of sphingosine-1-phosphate. Mol Biol Cell (2007) 1.30
The IKK-NF-kappaB pathway: a source for novel molecular drug targets in pain therapy? FASEB J (2008) 1.29
Current evidence for a genetic modulation of the response to analgesics. Pain (2006) 1.27
The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics (2006) 1.27
Discovery and characterization of a Ca2+-independent phosphatidylethanolamine N-acyltransferase generating the anandamide precursor and its congeners. J Biol Chem (2006) 1.26
Reduced hyperalgesia in homozygous carriers of a GTP cyclohydrolase 1 haplotype. Eur J Pain (2008) 1.26
Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem J (2004) 1.25
Specific Inhibition of IkappaB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats. J Neurosci (2004) 1.24
Temporal dynamics of mouse hippocampal clock gene expression support memory processing. Hippocampus (2010) 1.24
Rhythmic gene expression in pituitary depends on heterologous sensitization by the neurohormone melatonin. Nat Neurosci (2002) 1.22
Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol (2004) 1.21
G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res (2003) 1.20
Alterations in the hippocampal endocannabinoid system in diet-induced obese mice. J Neurosci (2010) 1.19
Biosynthetic pathways of the endocannabinoid anandamide. Chem Biodivers (2007) 1.18
Sphingosine kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages towards an anti-inflammatory phenotype. Int J Cancer (2009) 1.17
Long chain ceramides and very long chain ceramides have opposite effects on human breast and colon cancer cell growth. Int J Biochem Cell Biol (2012) 1.17
Peripheral opioid analgesia in experimental human pain models. Brain (2003) 1.17
Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis (2009) 1.15
Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med (2005) 1.14
Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation (2008) 1.14
Biology of endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat (2008) 1.14
Microglia promote colonization of brain tissue by breast cancer cells in a Wnt-dependent way. Glia (2010) 1.13
Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. Biochim Biophys Acta (2005) 1.12
Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition. FASEB J (2006) 1.12
Functional analysis of the purified anandamide-generating phospholipase D as a member of the metallo-beta-lactamase family. J Biol Chem (2006) 1.12
Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats. J Hypertens (2009) 1.11
Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease. PLoS One (2010) 1.11
cGMP produced by NO-sensitive guanylyl cyclase essentially contributes to inflammatory and neuropathic pain by using targets different from cGMP-dependent protein kinase I. J Neurosci (2008) 1.10
Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J (2005) 1.10
A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem (2008) 1.10
Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. Pharmacogenet Genomics (2009) 1.10
Treatment options for subjective tinnitus: self reports from a sample of general practitioners and ENT physicians within Europe and the USA. BMC Health Serv Res (2011) 1.10
The tumor suppressor gene H-Rev107 functions as a novel Ca2+-independent cytosolic phospholipase A1/2 of the thiol hydrolase type. J Lipid Res (2008) 1.10
FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions. Mol Immunol (2007) 1.09
Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology (2002) 1.09
Characterization of the human tumor suppressors TIG3 and HRASLS2 as phospholipid-metabolizing enzymes. Biochim Biophys Acta (2009) 1.09
R-flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids. PLoS One (2010) 1.08
Phenotyping the function of TRPV1-expressing sensory neurons by targeted axonal silencing. J Neurosci (2013) 1.06
Mammalian cells stably overexpressing N-acylphosphatidylethanolamine-hydrolysing phospholipase D exhibit significantly decreased levels of N-acylphosphatidylethanolamines. Biochem J (2005) 1.06
PAM mediates sustained inhibition of cAMP signaling by sphingosine-1-phosphate. EMBO J (2004) 1.06
N-cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase. Biochem J (2004) 1.05
Impact of MACC1 on human malignant glioma progression and patients' unfavorable prognosis. Neuro Oncol (2013) 1.05
Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol (2002) 1.05
The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis. J Lipid Res (2008) 1.04
Sphingosine 1-phosphate modulates spinal nociceptive processing. J Biol Chem (2008) 1.04
Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain (2009) 1.03
5,6-EET is released upon neuronal activity and induces mechanical pain hypersensitivity via TRPA1 on central afferent terminals. J Neurosci (2012) 1.03
N-acylphosphatidylethanolamine-hydrolyzing phospholipase D is an important determinant of uterine anandamide levels during implantation. J Biol Chem (2005) 1.00
Cleavage of sphingosine kinase 2 by caspase-1 provokes its release from apoptotic cells. Blood (2010) 1.00
Expression of cyclooxygenase-2 parallels expression of interleukin-1beta, interleukin-6 and NF-kappaB in human colorectal cancer. Carcinogenesis (2003) 1.00
Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics (2009) 0.99
Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther (2006) 0.99
PGD2 metabolism in plasma: kinetics and relationship with bioactivity on DP1 and CRTH2 receptors. Biochem Pharmacol (2007) 0.99
Celecoxib inhibits 5-lipoxygenase. Biochem Pharmacol (2008) 0.99
Wound inflammation in diabetic ob/ob mice: functional coupling of prostaglandin biosynthesis to cyclooxygenase-1 activity in diabetes-impaired wound healing. Diabetes (2005) 0.98
LC-MS/MS-analysis of sphingosine-1-phosphate and related compounds in plasma samples. Prostaglandins Other Lipid Mediat (2006) 0.98
Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice. Arterioscler Thromb Vasc Biol (2010) 0.98
Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments. Neuro Oncol (2013) 0.98
Dual effects of spinally delivered 8-bromo-cyclic guanosine mono-phosphate (8-bromo-cGMP) in formalin-induced nociception in rats. Neurosci Lett (2002) 0.98
Antioxidant activity of sestrin 2 controls neuropathic pain after peripheral nerve injury. Antioxid Redox Signal (2013) 0.98
Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer. Clin Pharmacol Ther (2003) 0.97
Peripheral and central antihyperalgesic effects of diclofenac in a model of human inflammatory pain. Clin Pharmacol Ther (2003) 0.97
Influence of dTMP on the phenotypic appearance and intracellular persistence of Staphylococcus aureus. Infect Immun (2007) 0.97
Enzymatic formation of N-acylethanolamines from N-acylethanolamine plasmalogen through N-acylphosphatidylethanolamine-hydrolyzing phospholipase D-dependent and -independent pathways. Biochim Biophys Acta (2011) 0.97
The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem Pharmacol (2008) 0.97
Current evidence for a modulation of nociception by human genetic polymorphisms. Pain (2007) 0.97